Otros idiomas Nirvana Life Sciences Inc.

Acciones

NIRV

CA6546521064

Diferido Canadian Securities Exchange Otros sitios de cotización 21:01:35 22/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,04 ^CAD	-20,00 %		-.--%	+100,00 %

02/04	Nirvana Life Sciences Inc. informa de los resultados del tercer trimestre y los nueve meses finalizados el 31 de enero de 2024	CI
02/01	Nirvana Life Sciences Inc. informa de los resultados del segundo trimestre y de los seis meses finalizados el 31 de octubre de 2023	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	02/04
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	02/01
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	01/11
Nirvana Life Sciences Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	28/10/23
Nirvana Life Sciences Inc. completed the acquisition of Medsmart Dispensary Inc.	31/07/23
Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	03/04/23
Nirvana Life Sciences Inc. Announces Resignation of Chris Hoffmeister from the Board of Directors	22/02/23
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	31/12/22
Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of Directors	09/11/22
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2022	29/09/22
Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two Thirds	07/09/22
Nirvana Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	29/08/22
Nirvana Life Sciences Inc. Announces License for A Delivery System for Psychedelic APIs	06/07/22
Nirvana Life Sciences Announces Approval to Build Vancouver Facility from Health Canada	28/06/22
Nirvana Life Sciences Announces Filing of Patent for Novel Isolation of 4-PO-Psilocin Prodrug Compound	23/06/22
Nirvana Life Sciences Announces Patent Filing	09/06/22
Nirvana Life Sciences Inc. Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study	02/06/22
Nirvana Life Sciences Inc. Announces the Appointment of Andrew Samann to Advisory Board	05/04/22
Nirvana Life Sciences Inc. Announce Further Progress with Development of Its Vancouver Research and Development Facility	25/03/22
Nirvana Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	16/03/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Nirvana Life Sciences Inc.

Acciones

NIRV

CA6546521064

Otros idiomas

Filtros